Inari Medical Reports Q3 Loss, Higher Revenue; 2024 Sales Midpoint Guidance Boosted; Shares Rise
Inari Medical (NARI) reported a Q3 net loss late Monday of $0.31 per diluted share, compared with net income of $0.05 a year earlier.
Analysts polled by Capital IQ expected a $0.18 loss.
Revenue in the three months ended Sept. 30 rose to $153.4 million from $126.4 million a year earlier.
Analysts surveyed by Capital IQ expected $150.7 million.
In 2024, the medical device company expects revenue of $601.5 million to $604.5 million versus the previous outlook of $594.5 million to $604.5 million.
Analysts project $600 million.
Inari said it continues to expect to reach sustained operating profitability in H1.
The company's shares rose 10% in after-hours activity.
Price: 47.00, Change: +4.44, Percent Change: +10.43
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
No relevant data is available